MedMira and Swiss Partner Vitest Sign Private Label Agreement for Africa

    HALIFAX, March 10 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, announced today that it is has established a private label
partnership with Vitest AG (Vitest). Vitest, an established private label
partner of MedMira, plans to market and sell MedMira rapid HIV tests in Africa
under the Vitest brand. This partnership will increase the availability of
quality rapid HIV tests in Africa, a market where an urgent need for testing
exists, with an estimated 22 million people infected with HIV and nearly 2
million newly infected each year. (www.unaids.org)
    "MedMira and Vitest are coming together to respond to a growing need and
to deliver, what we believe will be the highest quality and most superior
rapid HIV test available in the African market," said Dr. Jörg-Michael
Hollidt, CEO, Vitest AG. "The collaboration between our two companies enables
us to deliver quickly and efficiently a high quality, world class diagnostic
solution with the flexibility to meet the varied needs of public health and
private company testing programs in Africa."
    The partnership enables each company to bring their core skills and focus
together to achieve success in complex and highly competitive developing
markets such as Africa. Under the terms of the agreement, MedMira will
manufacture its complete line of rapid diagnostics, which includes HIV,
hepatitis and multiple tests built on the Company's patented and award-winning
rapid flow-through technology platform, for Vitest to market and sell through
various channels in Africa, including public health tenders and private
company-sponsored programs.
    "We know that Africa is where one of the greatest testing needs exists
and we now have the right partner in Vitest and the infrastructure in place to
serve this market profitably," said Hermes Chan, CEO, MedMira Inc. "Our newly
outsourced manufacturing capabilities will enable us to meet the volume and
pricing demands of this highly competitive, price-driven market. We look
forward to working closely with Vitest to establish a firm position in Africa
for the MedMira/Vitest products."
    Chan continued, "By integrating our efforts we can successfully meet the
pricing and volume requirements that the Africa market demands. The focus of
our partnership will be to deliver high volumes of quality rapid HIV tests at
market-driven prices."

    About Vitest

    Vitest AG is a privately held company based in Wollerau, Switzerland
(www.vitest.ch) with a corporate subsidiary in Germany (Vitest GmbH). Vitest
is manufacturer of medical rapid tests and known well for their high quality
products. The company provides doctors offices, clinics and government
institutions with innovative rapid tests. With the introduction of Vitest HIV
to the German market, Vitest takes the lead in the latest AIDS prevention
movement to reduce the number of new HIV infections in Germany, by making
better diagnostics more widely available. For more information about Vitest
Europe, please contact Christiane Ewel, Head of Marketing and Sales Europe
([e-mail]), Vitest GmbH, D -16761 Hennigsdorf, Neuendorfstrasse 24b,
Tel. [phone], Fax. [phone] or for Vitest International,
please contact Nicholas Dellaportas ([e-mail]), Director of
Business Development and Sales, Vitest AG, UK - 33 Thames Point, The
Boulevard, Imperial Wharf, London, SW6 2 SX, [phone], Fax. [phone]
5110.

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E

For further information: Andrea Young, Corporate Communications, (902)
450-1588, [e-mail]